Ajanta Pharma Ltd receives EIR from USFDA for Paithan facility

Ajanta Pharma Limited has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its manufacturing facility at Paithan, Maharashtra. The inspection has been classified as Voluntary Action Indicated (VAI).

The current Good Manufacturing Practices (cGMP) inspection of the Paithan facility was conducted by the USFDA from 13 April 2026 to 21 April 2026.

Shares of Ajanta Pharma Limited was last trading in BSE at Rs. 3325.75 as compared to the previous close of Rs. 3343.80. The total number of shares traded during the day was 3077 in over 389 trades.

The stock hit an intraday high of Rs. 3407.45 and intraday low of 3313.00. The net turnover during the day was Rs. 10324429.00.

Source : Equity Bulls

Keywords

AjantaPharma INE031B01049 Pharmaceuticals USFDA EIR PaithanFacility